Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Minetta C. Liu, MD"'
Autor:
Jessica A. Slostad, MD, Minetta C. Liu, MD, Jacob B. Allred, MS, Lori A. Erickson, MD, Kandelaria M. Rumilla, MD, Matthew S. Block, MD, PhD, Michael Keppen, MD, David King, MD, Svetomir N. Markovic, MD, PhD, Robert R. McWilliams, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 6, Pp 1012-1020 (2021)
Objective: To evaluate the prognostic significance of detectable circulating cell-free DNA (cfDNA) BRAF V600E/K mutations in patients with advanced melanoma enrolled in a clinical trial without BRAF-targeted therapy. Patients and Methods: BRAF V600E/
Externí odkaz:
https://doaj.org/article/eba5613feb94492ca5a70349231da792
Autor:
Sneha S Shukla, MD, Asha A Bhatt, MD, James W Jakub, MD, Malvika H Solanki, MBBS, MPH, PhD, Aparna S Kaur, MD, Minetta C Liu, MD, Kimberly S Corbin, MD, Jessica A Axmacher, MD
Publikováno v:
Radiology Case Reports, Vol 17, Iss 6, Pp 1901-1904 (2022)
This is a case of locally recurrent invasive secretory carcinoma of the breast during pregnancy, detected as a palpable mass in the reconstructed right breast of a 32-year-old female at 24 weeks gestation. The patient was initially diagnosed with sec
Externí odkaz:
https://doaj.org/article/33fa591570eb44ae87c45d2654ebf4ce
Autor:
Huffman BM; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Jurdi A; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Aleshin A; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Liu MC; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA., Klempner SJ; Brandon M. Huffman, MD, Division of GI Oncology, Dana-Farber Cancer Institute, Boston, MA; Adham Jurdi, MD and Alexey Aleshin, MD, MBA, Natera, Inc, Austin, TX; and Minetta C Liu, MD and Samuel J. Klempner, MD, Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA.
Publikováno v:
JCO precision oncology [JCO Precis Oncol] 2023 Mar; Vol. 7, pp. e2300043.